Switching P2Y12-receptor inhibitors in patients with coronary artery disease

Nature Reviews Cardiology

Volumn 13, Issue 1, 2016, Pages 11-27

  Rollini, Fabiana ^a   Franchi, Francesco ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; CARDIAC PATIENT; CLINICAL PRACTICE; DRUG BINDING SITE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; HUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; CHRONIC DISEASE; CORONARY ARTERY DISEASE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; CHRONIC DISEASE; CORONARY ARTERY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84951574126     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.113     Document Type: Review

References (98)

1. Levine, G. N., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124, e574-e651 (2011).
2. OGara, P. T., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127, 529-555 (2013).
3. Amsterdam, E. A., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130, e344-e426 (2014).
4. Windecker, S., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35, 2541-2619 (2014).
5. Sherwood, M. W., et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J. Am. Heart Assoc. 3, e000849 (2014).
6. Bueno, H., et al. Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: insights from EPICOR, an international study of current practice patterns. Eur. Heart J. Acute Cardiovasc. Care http://dx.doi.org/10.1177/2048872614565912.
7. Wallentin, L., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
8. Wiviott, S. D., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
9. Dean, B. B., et al. Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. Am. J. Health Syst. Pharm. 67, 1430-1437 (2010).
10. Valgimigli, M. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. Circulation 130, 1891-1903 (2014).
11. Collet, J. P., Silvain, J., Bellemain-Appaix, A. & Montalescot, G. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation 130, 1904-1914 (2014).
12. Capodanno, D. & Angiolillo, D. J. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: a review of the evidence and practice guidelines. Circ. Cardiovasc. Interv. 8, e002301 (2015).
13. Azmoon, S. & Angiolillo, D. J. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheter. Cardiovasc. Interv. 81, 232-242 (2013).
14. Angiolillo, D. J., Ueno, M. & Goto, S. Basic principles of platelet biology and clinical implications. Circ. J. 74, 597-607 (2010).
15. Franchi, F. & Angiolillo, D. J. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12, 30-47 (2015).
16. Gachet, C. ADP receptors of platelets and their inhibition. Thromb. Haemost. 86, 222-232 (2001).
17. Dav, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
18. Storey, R. F., et al. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br. J. Haematol. 110,925-934 (2000).
19. Angiolillo, D. J. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 72, 2087-2116 (2012).
20. Storey, R. F. Biology and pharmacology of the platelet P2Y12 receptor. Curr. Pharm. Des. 12, 1255-1259 (2006).
21. Farid, N. A., Kurihara, A. & Wrighton, S. A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50, 126-142 (2010).
22. Price, M. J., et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J. Am. Coll. Cardiol. 59, 2338-2343 (2012).
23. Husted, S. & van Giezen, J. J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc. Ther. 27, 259-274 (2009).
24. Franchi, F., Rollini, F., Muniz-Lozano, A., Cho, J. R. & Angiolillo, D. J. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev. Cardiovasc. Ther. 11, 1279-1291 (2013).
25. Ueno, M., Rao, S. V. & Angiolillo, D. J. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 6, 445-453 (2010).
26. Welsh, R. C., et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ. Cardiovasc. Interv. 5, 336-346 (2012).
27. Angiolillo, D. J., et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ. Cardiovasc. Interv. 5, 347-356 (2012).
28. Gurbel, P. A., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577-2585 (2009).
29. Angiolillo, D. J., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J. Thromb. Thrombolysis 34, 44-55 (2012).
30. van Giezen J. J. & Humphries R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005).
31. European Medicines Agency. Annex I. Summary of product characteristics [online], http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003773/WC500188098.pdf (2015).
32. US Food and Drug Administration. Highlights of Prescribing Information. Kengreal™ (cangrelor) for injection, for intravenous use. [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/204958lbl.pdf (2015).
33. Roe, M. T., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367, 1297-1309 (2012).
34. Alexopoulos, D., et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am. Heart J. 167, 68-76.e2 (2014).
35. Clemmensen, P., et al. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel - the European MULTIPRAC Registry. Eur. Heart J. Acute Cardiovasc. Care 4, 220-229 (2015).
36. Bagai, A., et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the TRANSLATE-ACS study. Eur. Heart J. Acute Cardiovasc. Care http://dx.doi.org/10.1177/2048872614564082.
37. De Luca, L., et al. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT Study. Eur. Heart J. Acute Cardiovasc. Care http://dx.doi.org/10.1177/2048872614560505.
38. Bagai, A., et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ. Cardiovasc. Interv. 7, 585-593 (2014).
39. De Luca, G., et al. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. J. Thromb. Thrombolysis 38, 388-394 (2014).
40. Loh, J. P., et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am. J. Cardiol. 111, 841-845 (2013).
41. Almendro-Delia, M., et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the real world. J. Thromb. Thrombolysis 39, 499-507 (2015).
42. Payne, C. D., et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 19, 275-281 (2008).
43. Wiviott, S. D., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116, 2923-2932 (2007).
44. Montalescot, G., et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb. Haemost. 103, 213-223 (2010).
45. Angiolillo, D. J., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J. Am. Coll. Cardiol. 56, 1017-1023 (2010).
46. Trenk, D., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll. Cardiol. 59, 2159-2164 (2012).
47. Diodati, J. G., et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ. Cardiovasc. Interv. 6, 567-574 (2013).
48. Sardella, G., et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE trial. Circ. Cardiovasc. Interv. 5, 698-704 (2012).
49. Lhermusier, T., et al. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int. J. Cardiol. 174, 874-876 (2014).
50. Alexopoulos, D., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J. Am. Coll. Cardiol. 60, 193-199 (2012).
51. Koul, S., et al. A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC Cardiovasc. Disord. 14, 189 (2014).
52. Cuisset, T., et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int. J. Cardiol. 168, 523-528 (2013).
53. Nührenberg, T. G., et al. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets 24, 549-553 (2013).
54. Parodi, G., et al. Switching from clopidogrel to prasugrel in patients having coronary stent implantation. J. Thromb. Thrombolysis 38, 395-401 (2014).
55. Aradi, D., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J. Am. Coll. Cardiol. 63, 1061-1070 (2014).
56. Mayer, K., et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb. Haemost. 112, 342-351 (2014).
57. Lhermusier, T., et al. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J. Interv. Cardiol. 27, 365-372 (2014).
58. Gurbel, P. A., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121, 1188-1199 (2010).
59. Caiazzo, G., et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ. Cardiovasc. Interv. 7, 104-112 (2014).
60. Hibbert, B., et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS ONE 9, e92078 (2014).
61. Bliden, K. P., et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am. Heart J. 162, 160-165 (2011).
62. Storey, R. F., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J. Am. Coll. Cardiol. 56, 1456-1462 (2010).
63. Michelson, A. D., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 30, 1753-1763 (2009).
64. Saucedo, J. F., et al. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb. Haemost. 109, 347-355 (2013).
65. Bagai, A., et al. High on-treatment platelet reactivity among contemporary acute myocardial infarction patients treated with percutaneous coronary intervention: insights from the TRANSLATE-ACS study [abstract]. J. Am. Coll. Cardiol. 62 (Suppl. 1), B47 (2013).
66. Bernlochner, I., et al. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb. Haemost. 109,517-524 (2013).
67. Siller-Matula, J. M., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int. J. Cardiol. 167, 2018-2023 (2013).
68. Tantry, U. S., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62, 2261-2273 (2013).
69. Price, M. J., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097-1105 (2011).
70. Collet, J. P., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100-2109 (2012).
71. Franchi, F., Rollini, F., Cho, J. R., Ferrante, E. & Angiolillo, D. J. Platelet function testing in contemporary clinical and interventional practice. Curr. Treat. Options Cardiovasc. Med. 16, 300 (2014).
72. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01959451 (2015).
73. Bergmeijer, T. O., et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients - rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am. Heart J. 168, 16-22.e1 (2014).
74. Pourdjabbar, A., et al. Optimizing crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome: the CAPITAL OPTI-CROSS randomized trial [abstract]. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/S0735-1097(15)60108-5.
75. Kerneis, M., et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc. Interv. 6, 158-165 (2013).
76. Deharo, P., et al. Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Int. J. Cardiol. 168, 5004-5005 (2013).
77. Angiolillo, D. J. & Rollini, F. Switching from prasugrel to clopidogrel: navigating in unknown waters. JACC Cardiovasc. Interv. 6, 166-168 (2013).
78. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02287909 (2014).
79. Storey, R. F., et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur. Heart J. 32, 2945-2953 (2011).
80. Gaubert, M., et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int. J. Cardiol. 173, 120-121 (2014).
81. Bonaca, M. P., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791-1800 (2015).
82. Angiolillo, D. J., et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J. Am. Coll. Cardiol. 63, 1500-1509 (2014).
83. Bassez, C., et al. Effectiveness of switching low responders to prasugrel to ticagrelor after acute coronary syndrome. Int. J. Cardiol. 176, 1184-1185 (2014).
84. US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02016170 (2015).
85. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01869309 (2014).
86. Steinhubl, S. R., et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121, 527-534 (2008).
87. Dovlatova, N. L., Jakubowski, J. A., Sugidachi, A. & Heptinstall, S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost. 6, 1153-1159 (2008).
88. Rollini, F., et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc. Interv. 7, 426-434 (2014).
89. Angiolillo, D. J., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307, 265-274 (2012).
90. Bhatt, D. L., et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330-2341 (2009).
91. Harrington, R. A., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361, 2318-2329 (2009).
92. Bhatt, D. L., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368, 1303-1313 (2013).
93. White, H. D., et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am. Heart J. 163, 182-190.e4 (2012).
94. Schneider, D. J., Seecheran, N., Raza, S. S., Keating, F. K. & Gogo, P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron. Artery Dis. 26, 42-48 (2015).
95. Schneider, D. J., Agarwal, Z., Seecheran, N., Keating, F. K. & Gogo, P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc. Interv. 7, 435-442 (2014).
96. Ravnefjord A., Weilitz J., Emanuelsson B. M. & van Giezen J. J. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y12 antagonists in an ex-vivo canine model. Thromb. Res. 130, 622-628 (2012).
97. US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01991795 (2015).
98. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01732822 (2015).